Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sharona Ben-Haim

Neurological Surgery San Diego, CA Medical Doctor

NPI 1942469663 CMS profile 1388028

200 W Arbor Dr, San Diego, CA 92103

Open in the dashboard

General payments

$23,889

179 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sharona Ben-Haim of San Diego, CA is reported in the CMS Open Payments database as having received $23,889 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,122 30
2024 General $15,090 52
2023 General $1,213 22
2022 General $981 13
2021 General $450 11
2020 General $247 9
2019 General $1,786 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharona Ben-Haim
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Sharona Ben-Haim were reported at $4,122. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Sharona Ben-Haim Neurological Surgery median Middle half National median
2019 $1,786 $582 $138–$3,006 $163
2020 $247 $294 $76–$2,174 $114
2021 $450 $387 $105–$2,432 $132
2022 $981 $542 $139–$2,989 $149
2023 $1,213 $534 $145–$2,697 $160
2024 $15,090 $574 $155–$3,046 $164
2025 $4,122 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $10,474 46 payments
  2. Boston Scientific Corporation $9,870 51 payments
  3. Medtronic, Inc. $1,708 37 payments
  4. Nevro Corp. $550 7 payments
  5. Monteris Medical Corporation $293 10 payments
  6. ClearPoint Neuro, Inc. $267 5 payments
  7. Medtronic USA, Inc. $249 6 payments
  8. InSightec,Inc $121 2 payments
  9. NeuroPace, Inc. $111 5 payments
  10. Merz North America, Inc. $100 1 payment
  11. Other $146 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,800 6 payments
  2. Food and Beverage $7,919 155 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,675 5 payments
  4. Travel and Lodging $2,137 10 payments
  5. Grant $356 1 payment
  6. Education $2 2 payments
Products named General payments · program years 2019–2025
  1. INFINITY Neuromodulation $9,939 28 payments
  2. Vercise Vercise_NMD $6,875 8 payments
  3. PERCEPT PC BRAINSENSE $904 27 payments
  4. General - DBS $818 12 payments
  5. Senza Spinal Cord Stimulation System $474 6 payments
  6. VERCISE Dbs $443 6 payments
  7. VISUALASE $384 2 payments
  8. CLEARPOINT $267 5 payments
  9. Neuroblate $202 9 payments
  10. INFINITY Structural Heart $175 2 payments
  11. Other $1,757 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$77,835

Medicare's payments for the services billed

Medicare patients

106

Average age 67

Services billed

207

51 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 50%
Depression 36%
Diabetes 32%
Ischemic heart disease 24%
Chronic kidney disease 19%
Atrial fibrillation 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record